|
|
Appreciation from BioNTX for a Successful 2025 iC³ Summit |
|
|
|
Dear Friends, Partners, and Supporters,
Thank you for making the 2025 iC³® Life Science & Healthcare Innovation Summit an outstanding success. The energy, ideas, and commitment you brought—whether as attendees, sponsors, speakers, or partners—are what gave this year’s Summit its true impact.
Together, we explored the breakthroughs shaping our industry, strengthened connections across disciplines, and affirmed the role North Texas plays in advancing life science and healthcare innovation. These moments of collaboration are at the heart of BioNTX’s mission, and it was inspiring to see them in action.
We are deeply grateful for your support and partnership. As we look ahead, BioNTX is committed to building on this momentum, creating even greater opportunities to innovate, connect, and grow our community in the years to come.
On behalf of BioNTX, thank you for walking with us into the next decade and beyond. |
|
|
The State of Biotech in Texas: 2025 Insights |
|
|
At the 2025 iC³ Life Science & Healthcare Innovation Summit, BioNTX spotlighted the EY Biotech Beyond Borders Report 2025: Texas Edition, highlighting Texas as a resilient and innovative hub in the global biotech sector. Despite funding challenges and evolving markets, Texas biotech companies continue to adapt, forge strategic partnerships, and leverage technology to drive growth and resilience. |
|
Texas Biotech Charts a Bold Future at the 2025 iC³ Summit |
|
|
|
Texas biotech companies continue to face headwinds from a post-pandemic bear market and reduced funding, according to the recent Texas EY Biotech Beyond Borders Report. Still, industry leaders see reasons for optimism as new state policies begin to take shape. Advances in artificial intelligence are also opening new opportunities for research and commercialization. At the same time, potential federal reforms, including regulatory changes, could further boost competitiveness. These themes took center stage at the 2025 BioNTX iC³ Life Science & Healthcare Innovation Summit, held September 16–17 in Dallas. |
|
COMING SOON |
|
BIO BREAK is Back and Expanding |
|
|
BIO BREAK is expanding—continuing in Dallas, Fort Worth, and now adding Frisco—offering more opportunities to connect, share ideas, and spark collaboration across our ecosystem.
With the momentum of the iC³ Summit carrying us forward, let’s finish the year strong and keep building the relationships that drive life science and healthcare innovation in North Texas. |
|
From Lab to Launch: Navigating Facilities in Life Sciences October 15, 2025 |
|
|
Presents |
|
|
Join the BioNTX Facilities Committee to hear a discussion on guiding small companies through the critical transition from research to production. We will dive into the different paths companies can take to scale their operations, including utilizing co-working facilities such as BioLabs and Bridge Labs, collaborating with contract development and manufacturing organizations (CDMOs), or taking on the challenge of building your own facility from the ground up or through strategic renovations. |
|
MEMBER SPOTLIGHT |
|
Celebrating 60 Years of Continued Excellence |
|
|
LPA Design Studios, one of the nation’s largest integrated design firms, was recently honored with the 2025 AIA Architecture Firm Award, the highest recognition in U.S. architecture. With more than 500 professionals across California and Texas, LPA has become a leader in blending sustainability, performance, and innovation across education, healthcare, civic, and commercial projects.
Beyond award-winning design, LPA is making an impact through community and workforce initiatives. Its Diversity in Design Scholarship supports students from underrepresented backgrounds entering the profession, while its “60 Acts of Kindness” campaign mobilizes employees in volunteer service nationwide. Together, these efforts reflect LPA’s vision of shaping not just buildings, but stronger, more sustainable communities. |
|
MEMBER NEWS |
|
CAGE Bio Announces Positive Phase 2b Results for CGB-500 in Atopic Dermatitis |
|
|
CAGE Bio, a biotechnology company developing ionic liquid–based therapies for immune-mediated skin diseases, reported positive topline results from its Phase 2b trial of CGB-500 in patients with moderate-to-severe atopic dermatitis affecting less than 10% of body surface area. The trial demonstrated rapid and sustained itch relief, high rates of skin clearance, and a favorable safety profile, highlighting CGB-500’s potential as a safe, effective, localized alternative to systemic treatments. |
|
Colossal Biosciences Achieves Historic Breakthrough in Dodo Revival |
|
|
Colossal Biosciences, the world’s de-extinction company, announced a historic breakthrough in avian science: for the first time, its Avian Genetics Group has successfully grown pigeon primordial germ cells (PGCs), a key step toward bringing back the dodo.
The team has also expanded its gene-edited chicken flock to serve as potential dodo surrogates and generated genomic resources to guide restoration efforts, extending PGC technology beyond chickens and geese. Colossal has formed the Mauritius Dodo Advisory Committee to guide conservation efforts and the eventual rewilding of dodos in their native habitat. |
|
Lantern Pharma Reports Promising Phase 1a Results for LP-184 |
|
|
Lantern Pharma Inc. is an AI-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer therapies. The company announced successful Phase 1a results for LP-184 in advanced solid tumors, demonstrating a strong safety profile with minimal high-grade toxicities and early signs of antitumor activity, including in heavily pretreated GBM and DDR-deficient cancers. The recommended Phase 2 dose of 0.39 mg/kg supports upcoming Phase 1b/2 studies in TNBC, NSCLC, and other DDR-driven tumors, with full results to be presented at future oncology conferences. |
|
Nanoscope Therapeutics Advances MCO-010 with EMA Orphan and FDA RMAT Designations |
|
|
Nanoscope Therapeutics, developing disease-agnostic therapies for retinal degeneration, announced EMA Orphan designations for MCO-010 across five retinal dystrophies and FDA RMAT designation for Stargardt disease. MCO-010 is a one-time, in-office therapy designed to restore vision without genetic testing or surgery. Positive Phase 2b/3 RP and Phase 2 SD results support upcoming Phase 3 and Phase 2 trials, positioning MCO-010 as a potential transformative treatment for millions of patients with vision loss. |
|
NemaLife Accelerates Discovery of Bioactives that Support Healthy Aging |
|
|
|
NemaLife, a biotechnology company advancing human relevant research with its high throughput C. elegans platform, played a key role in a new Nature Aging study identifying naturally occurring terpenoids, thymol and carvacrol, as potent activators of autophagy and mitophagy.
The study demonstrates how these compounds from common herbs can enhance cellular stress resilience and support healthy aging. NemaLife’s platform provided organism level insights that connected molecular mechanisms to functional outcomes, accelerating the translation of natural bioactives into nutrition based strategies to combat age related diseases. |
|
CleanSpace Expands to Pegasus Park, Launches First-of-its-Kind Cleanroom Showroom |
|
|
|
CleanSpace, a national leader in modular cleanroom design and construction, announced a strategic partnership with Pegasus Park, becoming the design-builder of choice for life science and innovation companies at the Dallas campus. As part of the expansion, CleanSpace opened its newest regional office and unveiled a 5,000-square-foot cleanroom showroom, showcasing fully operational, scalable environments from ISO 5 to ISO 8. |
|
Ecolab’s GBS+ Named a Top 20 Global Shared Services Organization |
|
|
Ecolab Inc., a global leader in water, hygiene, and infection prevention solutions, announced that its shared services platform, GBS+, has been recognized for the first time as one of the Top 20 Most Admired Shared Services Organizations and Global Business Services for 2025 by SSON Research & Analytics. This recognition reflects GBS+’s AI-enabled, end-to-end process approach and the exceptional performance of teams across five global service centers. By integrating cross-functional talent, scalable technologies, and process excellence, GBS+ supports Ecolab’s growth while delivering industry-leading experiences to customers, suppliers, and associates worldwide. |
|
GCS Launches Advanced Automated Cleanroom Panel Manufacturing Line |
|
|
GCS, a leading provider of modular cleanroom systems, announced the launch of a state-of-the-art automated cleanroom panel manufacturing line at its 265,000 sq. ft. U.S. facility. One of the largest of its kind in the country, the new line expands GCS’s capacity to produce over 2 million sq. ft. of cleanroom panels annually, supporting faster, precision manufacturing for pharmaceutical, biotechnology, semiconductor, and advanced technology industries.
The facility integrates high-speed automation and engineering to deliver scalable, repeatable, and compliant panels, including walkable and non-walkable ceiling panels and walls. This investment reinforces GCS’s position as a leader in modular cleanroom solutions and accelerates offsite construction for high-growth sectors. |
|
PHC Corporation’s LiCellMo Wins 2025 R&D 100 Award |
|
|
|
PHC Corporation’s Biomedical Division has been honored with a 2025 R&D 100 Award for its innovative live cell metabolic pathway analyzer, LiCellMo. Launched in Japan in September 2024 and subsequently in the United States, UK, EU, China, and select Asian markets, LiCellMo provides continuous real-time monitoring of cellular metabolic pathways, offering unprecedented insight into dynamic cell states. |
|
Transcat Expands Liquid Flow Calibration Services Across Industries |
|
|
Transcat, a leading provider of calibration, compliance, and laboratory services, announced the expansion of its liquid flow calibration capabilities, now supporting nearly every flowmeter type and manufacturer. This enhancement enables customers across chemical processing, automotive, aerospace, and medical device industries to ensure precision and confidence in flow measurement and control.
The expanded service covers Coriolis, electromagnetic, turbine, ultrasonic (including clamp-on), gear, positive displacement, variable area, orifice, vortex, and other critical meters, including large diameter flowmeters up to two inches, all fully traceable to NIST standards. Highly trained technicians tailor each calibration to the instrument’s application, flow rate, and operating conditions, delivering best-in-class service and customer experience. |
|
TWU Launches Center for Leadership Research and Workforce Development |
|
|
The Jane Nelson Institute for Women’s Leadership at Texas Woman’s University has launched the Center for Leadership Research and Workforce Development, a dual-mission initiative aimed at advancing women’s leadership research while transforming how students develop essential career skills. The center integrates scholarly research on leadership trends with evidence-based methods for teaching skills such as critical thinking, communication, emotional intelligence, AI literacy, and ethical reasoning. |
|
UNT Health Fort Worth and TCC Empower Students to Shape the Future of Healthcare |
|
|
|
Twenty-four Tarrant County College students participated in the Summer Academy of Health Science (SAHS), a collaborative program with UNT Health Fort Worth designed to immerse students in the careers of the future. Now in its third year, SAHS introduces students to roles as providers, researchers, educators, and leaders in healthcare and public health.
Over 5 weeks, students gained hands-on experience in clinical labs, pharmacy compounding, physical therapy simulations, forensic studies, and public health initiatives. They also engaged with faculty and professionals who shared personal career journeys, helping students see the diverse paths to impact in health sciences. |
|
UTA Ranked for Excellence in Health, Sustainability, and Equity |
|
|
The University of Texas at Arlington has earned recognition in the 2025 Times Higher Education Impact Rankings for its continued progress in supporting the United Nations Sustainable Development Goals (SDGs). These goals aim to tackle pressing global challenges including poverty, inequality, health, education, and climate change.
This recognition highlights UT Arlington’s growing global impact and its continued leadership in driving sustainable progress through innovation, collaboration, and a long-standing dedication to building healthier, more resilient communities. |
|
UT Dallas Researchers Develop Miniature Imaging Device to Detect Cancer Earlier |
|
|
|
Baowei Fei, PhD |
|
Researchers at the University of Texas at Dallas have developed a compact hyperspectral imaging device that could be integrated with an endoscope to detect cancers at earlier stages. Unlike conventional cameras, the device captures visible, near-infrared, and ultraviolet light, producing spectral “fingerprints” that reveal subtle differences in tissue.
Led by Dr. Baowei Fei at the Erik Jonsson School of Engineering and Computer Science, the team has combined hyperspectral imaging with artificial intelligence to identify and predict cancer cells in real time. The LED-based prototype, already tested on tissue samples, is small enough for endoscopic use and aims to improve detection in digestive system cancers, which remain among the most common and deadly in the U.S. |
|
UT Southwestern Named National Liver Cancer SPORE Center |
|
|
|
The principal investigators at UT Southwestern Medical Center involved in the Specialized Program of Research Excellence (SPORE) for liver cancer are
(from left to right) Hao Zhu, MD, Amit Singal, MD, MS, David Hsieh, MD, Yujin Hoshida, MD, PhD, Adam Yopp, MD, and Daolin Tang, MD, PhD.
|
|
The Liver Tumor Program at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center has been selected by the National Cancer Institute as a Specialized Program of Research Excellence (SPORE). Co-led by Drs. Yujin Hoshida and Amit Singal, the program aims to accelerate the development of precision interventions to prevent and treat liver cancer, with a focus on hepatocellular carcinoma (HCC), which accounts for more than 85% of U.S. liver cancer cases.
Texas has one of the highest rates of HCC in the nation, underscoring the importance of this research. The SPORE designation will support three major research projects designed to translate innovative discoveries into therapies that reduce incidence and mortality, improving outcomes for patients. UT Southwestern joins Mayo Clinic and MD Anderson as leading liver cancer SPORE centers in the United States. |
|
FUNDING & MENTORSHIP OPPORTUNITIES |
|
Propionic Acidemia Foundation Application closes October 1, 2025 |
|
|
PAF is a non-profit organization whose primary mission is to help advance research devoted to finding treatments and a cure for propionic acidemia. By funding research, we aim to accelerate new knowledge, discovery, development and/or evaluation of therapeutics leading to better treatment and a cure for all individuals affected by PA.
Funding available for Research projects and Post-Doctoral Fellows Program. |
|
Nucleate Activator Program Application closes October 15, 2025 |
|
|
Are you a scientific trainee (PhD, Post-doc, MBA, MD, JD) interested in launching a biotech or sustainability-focused startup? Are you working on innovations in therapeutics, diagnostics, medtech, synthetic biology, or tackling challenges in food, energy, agriculture, or consumer products?
Apply now to join Nucleate’s Activator program, the largest scientist-led biotech accelerator supporting ventures at the intersection of human and planetary health. |
|
ARPA-H Give Application closes October 19, 2025 |
|
|
GIVE is aimed at creating distributed biomanufacturing and quality control platforms for genetic medicines and cell therapies to enable onsite production and access. Projects should focus on overcoming key challenges to manufacturing genetic medicines including manufacturing costs, the reliance on a discrete subset of locations that provide unique centralized equipment, resource intensive quality control systems, and the need for ultracold storage and shipping of finished products.
Through this program, ARPA-H aims to bolster U.S. biomanufacturing technology to ensure personalized and individualized genetic medicines are made domestically, improving patient access to cancer therapies, cell therapies, and gene editing technologies. Applicants should ensure strong expertise in automation, device integration, and quality systems to compete in this infrastructure-oriented space. |
|
ARPA-H THRIVE Application closes October 31, 2025 |
|
|
THRIVE aims to make personalized and affordable cures available to all rare disease patients. The program intends to develop pioneering integrated platform technologies to accelerate precision genetic medicines (PGMs) and provide single-intervention precision treatments to slow, reverse, or prevent chronic diseases at the genetic level. THRIVE is designed to optimize affordability, scalability, and sustainability of lifesaving PGMs for patients through existing regional treatment centers and virtual clinics. This will allow patients to be seen and treated where they live. |
|
Fueling the Next Generation of Health Innovators Application closes March 6, 2026 |
|
|
The One Health Incubator is a dynamic partnership between the Innovation Hub and the Health Sciences Center, created to support researchers and technology startups in the life sciences sector. This collaborative platform combines institutional expertise to offer an ecosystem of incubation, mentorship, and strategic connections—tailored specifically for life science innovators.
Startups and researchers benefit from access to state-of-the-art facilities, specialized resources, and guidance from industry experts. The incubator helps accelerate the development and commercialization of innovative healthcare solutions while fostering valuable relationships with potential partners, investors, and mentors. |
|
NIH Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions Program ends January 8, 2027 |
|
|
The purpose of this Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions is to support small scale research grants at institutions that do not receive substantial funding from the NIH, with an emphasis on providing biomedical research experiences primarily for undergraduate students, and enhancing the research environment at applicant institutions. |
|
INDUSTRY EVENTS |
|
Upcoming Events & Opportunities |
|
|
Fall Policy & Luminary Awards Dinner
Join THBI for their annual Fall Policy Summit, this is a half-day conference with conversations focused on the latest ground breaking research, federal policy initiatives, and what Texas biotech is doing to put patients at the forefront of innovation.
October 1st | Austin, TX |
|
|
Catalyst: The Future of Science, Business, and Health
Join Life Science Oklahoma for the inaugural Catalyst event, featuring Kathy VanEnkevort—Microsoft’s U.S. Health & Life Sciences Industry Leader. Kathy is a nationally recognized force in reimagining life science and healthcare.
October 3rd | Oklahoma City, OK |
|
|
Building Healthier Communities
Join Healthcare Think Tank for a warm and cozy fireside chat featuring Esmaeil Porsa, MD, MBA, MPH, CCHP-A, President and CEO of Harris Health System. Dr. Porsa is setting the bar for public health, making a significant impact in Houston, Harris County, and beyond.
October 6th | Houston, TX |
|
|
Support Proposition 14 in the Fight Against Alzheimer's
Join THBI for a special briefing on the importance of supporting Proposition 14, the impact this proposition will make on businesses and research in Texas, and how you and your company can help.
October 8th | Online |
|
|
Cocktails & Conversations
Join Ignite and Lyda Hill Philanthropies for a powerful fireside chat featuring entrepreneurs and investors who are on the front lines of this transformation. Together, they will share how they’re adapting, what insights they’ve gained, and where they see bright spots in an uncertain environment.
October 8th | Dallas, TX |
|
|
Unleashing Imagination: The Creative Brain & AI
Join the Center for BrainHealth in welcoming Dr. Adam Green. In an age driven by AI, neuroscientist Dr. Adam Green anticipates an increasing demand for human creativity. Leader of a National Science Foundation project on creativity in STEM, he seeks to measure innovative thinking as a predictor of success, gauge how different aspects of creativity may work together, and map the seemingly miraculous process of creative ideation.
October 9th | Dallas, TX |
|
|
Presents
BIO BREAK Fort Worth - Oktoberfest
Join BioNTX, RSM, and UMB Bank for a special Oktoberfest-themed happy hour at Boehringer Ingelheim, celebrating the life science community where ideas flourish, partnerships take root, and collaboration thrives.
October 14th | Fort Worth, TX |
|
|
Presents
So You Think You Need a Facility?
Join the BioNTX Facilities Committee to hear a discussion on guiding start-ups from research to production. We will cover options such as co-working spaces like BioLabs and Bridge Labs, partnering with CDMOs, or building your own facility from scratch or through renovations.
October 15th | Dallas, TX |
|
|
CRISPR Conversations: Ensuring Quality, Success, and Scale with Guide RNA
Join TriLink BioTechnologies to explore strategies for optimizing guide RNA quality, improving editing success, and scaling for translational and clinical applications. It is a great opportunity to connect with gene editing innovators and join the conversation on where the field is headed.
October 15th | Houston, TX |
|
|
IND 101
Join NCTM for an interactive workshop designed for research, medical, and biotech professionals who need a practical understanding of the Investigational New Drug (IND) process. Topics include preparing for and conducting a pre-IND meeting, IND format and content, and leveraging FDA’s expedited pathways.
October 23rd - 24th | Hybrid |
|
Thank you for your Membership & Support! "Look deep into nature, and then you will understand everything better." - Albert Einstein |
|
|
September 30, 2025 |
|
